Abstract

BackgroundRecruitment, enrollment and retention of volunteers in an HIV vaccine trial is important in the efforts to ultimately develop a vaccine that can prevent new HIV infections. Following recruitment, some randomized individuals decline to be enrolled in an HIV vaccine trial. The reasons for such a decision are not well known. This article describes why individuals who were randomized in a phase I and II HIV vaccine trial in Dar es Salaam, Tanzania declined to be enrolled.MethodsFace-to-face interviews were conducted with 14 individuals (7 men and 7 women). Repeated readings of the 14 interview transcripts to look for reasons for declining to enroll in the trial were performed. Data was analyzed using the content analysis approach.ResultsInformants expressed fear of the outcome of an experimental HIV vaccine in their lives. Unlike women, some men were concerned over the effect of the vaccine on their reproduction intentions. Women were concerned about the unknown effects of the vaccine in their bodies. Also, to a large extent, informants faced resistance from significant others such as fiancées, parents, relatives, and friends. Women were influenced by their potential intimate sexual partners; men were forbidden by their parents, and mothers had the most influential opinion.ConclusionsFear of the negative outcome of an experimental vaccine and resistance from significant others are the main reasons for declining to enroll in the HIV vaccine trial among eligible volunteers after randomization. The resistance from the significant others provides valuable guidance for designing future trials in Tanzania; for example, expanding the HIV vaccine trial education to the general population from the onset of the trial design.

Highlights

  • Throughout the world, only one HIV vaccine candidate has shown a modest efficacy in a phase III trial [1]

  • The purpose of this study was to understand why some individuals who were randomized in a Phase I and II HIV vaccine trial (HIVIS03) in Dar es Salaam, Tanzania, subsequently declined

  • Ethics statement This study draws material from a randomized double-blind phase I and II HIV vaccine trial research project conducted among healthy volunteers in Dar es Salaam, Tanzania [16]

Read more

Summary

Introduction

Throughout the world, only one HIV vaccine candidate has shown a modest efficacy in a phase III trial [1]. Women were concerned about the potential effects of HIV vaccine trial on their reproductive health [10,12,13]. They sensed that taking part in the trial would bring conflicts in their parental roles, negotiating safe sex with male partners, worries about being stigmatized, and being discriminated against [10]. Some randomized individuals decline to be enrolled in an HIV vaccine trial. The reasons for such a decision are not well known. This article describes why individuals who were randomized in a phase I and II HIV vaccine trial in Dar es Salaam, Tanzania declined to be enrolled

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call